Prognostic markers and new, innovative treatments in renal cell carcinoma.
We reviewed the current medical literature to present the prognostic markers and current treatments of Renal Cell Carcinoma (RCC) and to propose new and innovative treatments for RCC. A PubMed search (http://www.ncbi.nlm.nih.gov/PubMed/) was performed and prognostic markers in RCC were reviewed and presented here. We hypothesize our own innovative theoretical research in new treatments for RCC. This includes a combination formed of an anticancer vaccine (VAX-x), which prevents the emergence of drug-resistance to (DRUG-x), with its corresponding anticancer drug (DRUG-x), administrated after immunological response to (VAX-x), can be employed to successfully treat and cure RCC in its various stages. We therefore propose that new treatment options of RCC are possibly VAX-x with either of the tyrosine kinase inhibitors-sunitinib or sorafenib.
Ciprian C
CC
Secasan
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001557:Benzenesulfonates / Q000008:administration & dosage; D014408:Biomarkers, Tumor / Q000032:analysis*; D019496:Cancer Vaccines / Q000008:administration & dosage*; D002292:Carcinoma, Renal Cell / Q000175:diagnosis / Q000188:drug therapy; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007211:Indoles / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000175:diagnosis / Q000188:drug therapy; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D011725:Pyridines / Q000008:administration & dosage; D011758:Pyrroles / Q000008:administration & dosage; D000077157:Sorafenib; D000077210:Sunitinib; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D014408:Biomarkers, Tumor; D019496:Cancer Vaccines; D007211:Indoles; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D011758:Pyrroles; D009536:Niacinamide; D000077157:Sorafenib; D000077210:Sunitinib